SEATTLE, Sept. 13 /PRNewswire/ -- Immunex Corporation (Nasdaq: IMNX)
announced today that Leslie Garrison, M.D., MPH, will lead the Immunex
clinical development programs. Garrison, 42, will serve as senior vice
president, clinical development, a promotion from her current vice president
position at the company.
Dr. Garrison will take charge of the Immunex clinical development teams
for all marketed products and product candidates, including ENBREL(R)
(etanercept), NOVANTRONE(R) (mitoxantrone), LEUKINE(R) (sargramostim), and all
Immunex product candidates, including NUVANCE(TM) (IL-4 receptor), AVREND(TM)
(CD40 ligand), MOBISTA(TM) (flt3 ligand), TRAIL/Apo2L and other molecules in
the Immunex pipeline. She will also lead the biometrics, pharmacokinetics and
toxicology groups, with the respective vice presidents reporting directly to
her.
"As an 11-year veteran of Immunex, Leslie has played a pivotal role in the
clinical development of ENBREL and NUVANCE," said Peggy Phillips,
chief operating officer and executive vice president. "Her leadership skills
and extensive knowledge of drug development are valuable assets in the
critical link between discovery and commercialization."
A graduate of SUNY at Stony Brook School of Medicine and Johns Hopkins
University Graduate School of Hygiene and Public Health, Dr. Garrison was a
research fellow at Johns Hopkins University prior to joining Immunex, and she
also served as a clinical instructor in pediatrics at Johns Hopkins Hospital.
Dr. Garrison takes her position in succession to Ann Hayes, M.D., who
continues her work at Immunex as senior medical director, focusing on
Immunex's investigator IND program for ENBREL. After eight years of service
as the senior vice president, medical development, and a number of years in
the industry, Dr. Hayes will continue to play an important role in the future
clinical development of ENBREL.
Immunex Corporation is a biopharmaceutical company dedicated to improving
lives through immune system science innovations.
American Home Products Corporation owns a majority interest in Immunex.
AHP is one of the world's largest research-based pharmaceutical and
health care products companies. It is a leader in the discovery, development,
manufacturing and marketing of prescription drugs, including biotechnological
and vaccine products, animal health care products and over-the-counter
medications.
NOTE: This news release contains forward-looking statements that involve
risks and uncertainties, including risks associated with clinical development,
regulatory approvals, our reliance on third-party manufacturers, product
commercialization and other risks described from time to time in the SEC
reports filed by Immunex, including the most recently filed Form 10-Q. An
electronic version of this news release -- as well as additional information
about Immunex of interest to investors, customers, future employees and
patients -- is available on the Immunex home page at http://www.immunex.com.
SOURCE Immunex Corporation
 back to top
Related links:
http://www.immunex.com
Company News On-Call:
http://www.prnewswire.com/comp/434644.html or fax,
800-758-5804, ext. 434644
CONTACT:
media, Tim Warner, 206-479-4193, or
investors, Mark Leahy, 206-389-4363, both of Immunex Corporation
|
